KM-023

Phase 2Small molecule

KKamari Pharma Ltd

KM-023 is one of 5 small molecule programs targeting Pachyonychia Congenita. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pachyonychia CongenitaNot yet recruiting

Pachyonychia CongenitaPhase 2

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Pachyonychia Congenita

#DrugCompanyPhaseTrials

Rapamune

PPrism Pharmaceuticals

Approved

—2

PTX-022

PPalvella Therapeutics, Inc.

Phase 3

3 3

Zocor

KM-023

1 5

Simvastatine

TTel-Aviv Sourasky Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Pachyonychia Congenita

NCT07893483

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023

Completed·KKainos Medicine Inc.·Phase 1·NCT01348516·83 enrolled

TED1 trial

Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.

Recruiting·KKamari Pharma Ltd·Phase 1·NCT07090889·64 enrolled

Pachyonychia Congenita1 trial

Phase IIa Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of Oral KM-023 in Adult Patients With Palmoplantar Epidermal Differentiation Disorders - Pachyonychia Congenita (pEDD-PC): KRT6A-pEDD-PC, KRT6B-pEDD-PC, KRT6C-pEDD-PC, KRT16-pEDD-PC and KRT17-pEDD-PC

Not yet recruiting·OOrvida Pharma (formerly Kamari Pharma)·Phase 2·NCT07893483·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for KM-023. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KM-023 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KM-023. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kamari Pharma Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKamari Pharma Ltd

KM-023

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Single Ascending Dose1 trial

TED1 trial

Pachyonychia Congenita1 trial

References

Drug Info

Quick Facts

Related News